Amgen Inc. (AMGN) Position Held by Boulegeris Investments Inc.
Boulegeris Investments Inc. held its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,300 shares of the medical research company’s stock at the close of the second quarter. Boulegeris Investments Inc.’s holdings in Amgen were worth $224,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Canada Pension Plan Investment Board increased its stake in shares of Amgen by 65.7% in the second quarter. Canada Pension Plan Investment Board now owns 1,706,261 shares of the medical research company’s stock valued at $293,869,000 after buying an additional 676,300 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Amgen in the first quarter valued at approximately $110,402,000. Swiss National Bank increased its stake in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares during the period. Bank of Nova Scotia increased its stake in shares of Amgen by 414.4% in the first quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock valued at $98,747,000 after buying an additional 484,868 shares during the period. Finally, First Eagle Investment Management LLC acquired a new position in shares of Amgen in the second quarter valued at approximately $71,081,000. 78.20% of the stock is owned by hedge funds and other institutional investors.
Several research firms have recently issued reports on AMGN. Royal Bank Of Canada began coverage on Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective for the company. Bank of America Corporation upped their price objective on Amgen to $210.00 and gave the company a “buy” rating in a research note on Thursday, October 5th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and set a $196.00 target price (up previously from $189.00) on shares of Amgen in a research report on Friday, October 6th. Finally, Cann reissued a “buy” rating and set a $203.00 target price on shares of Amgen in a research report on Friday, October 6th. Thirteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. Amgen has an average rating of “Buy” and an average price target of $190.03.
Amgen Inc. (NASDAQ AMGN) opened at $169.38 on Thursday. The stock has a market capitalization of $123,499.17, a P/E ratio of 13.52, a price-to-earnings-growth ratio of 2.46 and a beta of 1.37. Amgen Inc. has a twelve month low of $138.83 and a twelve month high of $191.10. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company’s revenue for the quarter was down .7% compared to the same quarter last year. During the same period in the prior year, the business earned $3.02 EPS. sell-side analysts anticipate that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.
Amgen declared that its Board of Directors has initiated a share repurchase program on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.72%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s payout ratio is 41.63%.
In other Amgen news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the transaction, the executive vice president now owns 57,631 shares in the company, valued at $9,888,326.98. The disclosure for this sale can be found here. Insiders have sold a total of 7,050 shares of company stock worth $1,239,673 over the last 90 days. Company insiders own 0.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/16/amgen-inc-amgn-position-held-by-boulegeris-investments-inc.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.